Filing Flows › Retractable Technologies (RVP) › Q1 2026 › vs Q4 2025
Retractable Technologies (RVP) Q1 2026 vs Q4 2025 (quarter over quarter)
Retractable Technologies's revenue fell $2.3M (-24%) from $9.4M in Q4 2025 to $7.2M in Q1 2026. The biggest changes: EasyPoint Needles −$1.9M (-66%); Syringes −$371K (-6%); Blood Collection Products +$24K (+7%).
Retractable Technologies, Q1 2026: revenue $7.2M (-14% year over year), operating margin -85.9%, net loss $4.2M, operating cash flow −$1.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Syringes | $5.8M | $6.2M | −$371K | -6% |
| EasyPoint Needles | $993K | $2.9M | −$1.9M | -66% |
| Blood Collection Products | $375K | $351K | $24K | +7% |
| Other Products | $7K | $5K | $2K | +31% |
| Revenue | $7.2M | $9.4M | −$2.3M | -24% |
| Other income, net | $1.9M | $5.4M | −$3.4M | -64% |
| Net loss | $4.2M | $2.3M | $1.9M | +80% |
| Costs & expenses | $13.3M | $17.2M | −$3.8M | -22% |
| Operating costs | $13.3M | $17.2M | −$3.8M | -22% |
| Income tax | $2K | $2K | −$187 | -9% |
| Cost of revenue | $8.0M | $11.0M | −$3.0M | -27% |
| Research & development | $170K | $125K | $46K | +36% |
| Sales & marketing | $1.7M | $2.0M | −$238K | -12% |
| General & admin | $3.4M | $3.1M | $293K | +9% |
| Operating cash sources | $4.2M | $2.3M | $1.9M | +80% |
| Depreciation & amortization | $1.9M | $2.1M | −$239K | -11% |
| Working capital & other | $952K | −$393K | $1.3M | — |
| Cash used in operations | $1.4M | $597K | $772K | +129% |
| Net loss absorbed | $4.2M | $2.3M | $1.9M | +80% |
Questions
How much did Retractable Technologies's revenue grow quarter over quarter in Q1 2026?
Retractable Technologies's revenue fell $2.3M (-24%) from $9.4M in Q4 2025 to $7.2M in Q1 2026.
What drove Retractable Technologies's revenue change in Q1 2026?
EasyPoint Needles −$1.9M (-66%); Syringes −$371K (-6%); Blood Collection Products +$24K (+7%).